Malaria Vaccine Development Unit (mvdu)

疟疾疫苗开发单位（MVDU）概述：疟疾疫苗开发单位（MVDU）是NIAID与DMID密切合作的一项举措，旨在应对全球对疟疾疫苗的需求。在过去一年中，国家艾滋病研究所所长安东尼·福奇博士对这一问题的关注以及比尔和梅林达·盖茨基金会宣布对疟疾的支持进一步推动了这一努力。MVDU于2001年5月6日正式开放。我们现在已经生产了六种cGMP产品：AMA1 FVO，AMA1 3D7，MSP 1（42）FVO，MSP 1（42）3D7，Pfs 25，Pvs 25。我们正在开发另外两种产品的工艺：Pfs 48和Pvs 48。我们已完成Pvs 25的IND，并将很快提交AMA 1 FVO和AMA 1的IND。这意味着我们今年将进入Pvs25的试验，明年将进入AMA1的试验。整个装置现在转换为工业型实验室，并对质量进行工业型控制。

Malaria Vaccine Development Unit (MVDU) General Description: The Malaria Vaccine Development Unit (MVDU) is an NIAID initiative in close collaboration with DMID to respond to the global need for vaccines against malaria. This effort has been given additional impetus during the past year by the attention focused on this issue by Dr. Anthony Fauci, Director, NIAID, and by support for malaria announced by the Bill and Melinda Gates Foundation. The MVDU opened officially on May 6, 2001. We now have produced six cGMP products: AMA1 FVO, AMA1 3D7, MSP1(42) FVO, MSP1(42) 3D7, Pfs25, Pvs25. We are developing process for two more products: Pfs48 and Pvs48. We have completed the IND for Pvs25 and will soon submit the IND for AMA1 FVO and AMA1. This means that we will be entering trials with Pvs25 this year and AMA1 next year. The whole unit is now converted to an industrial type lab with the institution of industrial type control on quality.